- CohBar Inc And Morphogenesis Inc To Discuss Definitive Merger Agreement Call TranscriptMay 23, 2023
- Q3 2022 CohBar Inc Earnings Call TranscriptNov 08, 2022$2.27 (+2.25%)Earnings
- Q2 2022 CohBar Inc Earnings Call TranscriptAug 15, 2022$5.67 (-0.58%)Earnings
- Q1 2022 CohBar Inc Earnings Call TranscriptMay 16, 2022$5.96 (-3.17%)Earnings
- Q4 2021 CohBar Inc Earnings Call TranscriptMar 29, 2022$9.67 (+4.37%)Earnings
- Q3 2021 CohBar Inc Earnings Call TranscriptNov 15, 2021$19.8 (-5.32%)Earnings
- CohBar Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Q2 2021 CohBar Inc Earnings Call TranscriptAug 10, 2021$38.7Earnings
- Q1 2021 CohBar Inc Earnings Call TranscriptMay 17, 2021$36.6 (+1.67%)Earnings
- Q4 2020 CohBar Inc Earnings Call TranscriptMar 30, 2021$37.8 (-4.55%)Earnings
- Q3 2020 CohBar Inc Earnings Call TranscriptNov 16, 2020$34.5 (+5.50%)Earnings
- CohBar, Inc. - Special Call TranscriptNov 06, 2020
- Q2 2020 CohBar Inc Earnings Call TranscriptAug 13, 2020$45.6 (-1.94%)Earnings
- CohBar, Inc. - Special Call TranscriptJun 16, 2020
- CohBar Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Q1 2020 CohBar Inc Earnings Call TranscriptMay 14, 2020$71.4 (-12.50%)Earnings
- Q4 2019 CohBar Inc Earnings Call TranscriptMar 12, 2020$43.8 (-17.05%)Earnings
- Q3 2019 CohBar Inc Earnings Call TranscriptNov 06, 2019$57 (-7.77%)Earnings
- Q2 2019 CohBar Inc Earnings Call TranscriptAug 07, 2019$42.6 (-0.70%)Earnings
- CohBar, Inc. Investor Update TranscriptJun 18, 2019
- CohBar Inc Annual Shareholders Meeting TranscriptJun 18, 2019
- Q1 2019 CohBar Inc Earnings Call TranscriptMay 07, 2019$84.3 (+2.93%)Earnings
- CohBar, Inc. - Special Call TranscriptMay 02, 2019
- Q4 2018 CohBar Inc Earnings Call TranscriptMar 18, 2019Earnings
CohBar Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Welcome to the H.C. Wainwright 5th Annual NASH Conference. For our next presentation, we have Dr. Joseph Sarret, CEO of CohBar, a clinical stage company developing mitochondria-based therapeutics for chronic diseases. Dr. Sarret, very good to have you with us. Please go ahead with your presentation.
Thanks, Thomas. Appreciate the opportunity here to speak with you today and tell you more about CohBar and the exciting work we are doing in the area of NASH. Just as a reminder, CohBar is a public company so typical forward-looking statement warnings apply to my remarks today.
So CohBar, in terms of our overall approach, what we are doing is we are leveraging the power of mitochondrial genome to develop novel peptide therapeutics. As you may be aware, people have been looking at the nuclear genome for quite some time, but mitochondrial has been largely overlooked. I think for a couple of reasons. One is people tend to think of mitochondria in terms of ATP
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)